Latest Healthcare It News

dorsaVi has begun critical testing of its innovative RRAM-powered sensor systems in Singapore, targeting biomedical applications like EMG and ECG to enhance wearable device performance and energy efficiency.

Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.

SDI Limited reports a flat sales performance for FY25 with regional growth offset by declines in key markets, while advancing its Montrose facility project with funding plans underway.

Cochlear Limited has secured FDA approval for its latest Nucleus Nexa System and Kanso 3 sound processors, setting the stage for a US market debut in early FY26.

MedAdvisor Limited has finalized the sale of its Australian and New Zealand operations to Jonas Software for an estimated $42.35 million, marking a strategic pivot towards its US business. The company also announced upcoming CFO changes as it refocuses its growth trajectory.

Vection Technologies has landed a $4 million contract with Italy’s Omniacom Group to deploy its AI-integrated extended reality solutions across multiple sectors, marking a milestone in its European expansion.

ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.

EVE Health Group has placed its first commercial purchase order for Dyspro™, a cannabinoid-based pharmaceutical targeting painful menstruation, signaling a key step toward market entry. The product is set for manufacturing and distribution within weeks, tapping into a rapidly growing global women’s health market.

Nanosonics has launched trophon3, its next-generation ultrasound disinfection device, alongside a software upgrade for existing users, promising faster cycles and enhanced digital integration.

Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.

TruScreen Group Limited has corrected an administrative error in its Share Purchase Plan allocations, ensuring shareholders receive their proper pro-rata entitlements ahead of a key special meeting.

Enlitic has completed its $10 million capital raise, triggering a $2 million advance payment from GE HealthCare and cementing a strategic collaboration with significant revenue potential.